Loading stock…

STERIS plc (STE) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

STERIS plc

STEMarket cap $20BPrice $209.7

Country🇺🇸United States

SectorHealthcare

IndustryHealthcare Equipment

Sterilizes and sanitizes medical equipment for hospitals worldwide, making sure surgical tools don't kill patients before treatments do. Nearly every hospital in America relies on its infection-prevention technology, from operating rooms to dental clinics, every single day.

In Bastion Portfolios?

52W Return-12%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+9%7

Revenue Forecast

Rev CAGR (1y)+7%5

Rev CAGR (3y)+7%5

Rev CAGR (5y)+6%6

Earnings Forecast

EPS Growth Y+1+41%9

EPS Growth Y+2+9%6

EPS Growth Y+3+10%7

Quality

Margins

EBIT Margin19%7

Net Income Margin13%7

Free Cash Flow Margin15%7

Debt

Net Debt/EBITDA0.96

Efficiency

ROE11%5

ROA8%8

Earnings Stability77

GEAR+STRONG82

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)185

P/E Ratio (Forward 3y)164

P/BV2.85

EV Multiples

EV/EBITDA Fwd125

EV/EBIT Fwd146

Yield

Free Cash Flow Yield4.5%6

Dividend Yield1.3%4

Momentum

Short term

1 month return-4%6

3 month return+0%6

YTD return-17%3

Mid term

Price vs 52wHigh78%5

1 year return-13%3

Long term

3 year return-4%3

5 year return+0%4

Risk Shield

Price Risk

Beta0.48

Volatility25%8

Free Cash Flow

Free Cash Flow Margin15%7

Free Cash Flow Yield4.5%6

Quality

ROCE12%6

Earnings Stability77

Net Debt/EBITDA0.96

02Growth

Is it actually growing, and how fast?

STESTERIS

Revenue FY26$5.9B

GROWTH RATING↗

AVERAGE54 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+9%7

Revenue, next 1Y+7%5

Revenue, next 3Y, CAGR+7%5

Revenue, next 5Y, CAGR+6%6

EARNINGS FORECAST▾SCORE

EPS growth, FY27E+41%9

EPS growth, FY28E+9%6

EPS growth, FY29E+10%7

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 9%/yr over the last 3 years, ahead of 60% of companies worldwide.7/10

Earnings are set to grow in step with sales (EPS about 10%/yr vs revenue 7%/yr).

WATCH

A mid-pack grower, ahead of 54% of companies worldwide.

Revenue is set to grow 7%/yr over the next 3 years, in line with the market.5/10

Revenue grew 9%/yr over the last 3 years and is set to keep growing around 7%/yr.

Over five years revenue is set to grow 6%/yr, ahead of 50% of companies worldwide.6/10

WEAKNESSES

None flagged.

BOTTOM LINE

Margin Expander

A middle-of-the-pack grower. The one thing to watch: forward revenue growth is only about average.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

WEAK33 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-4%6

3-month return+0%6

YTD return-17%3

MID & LONG-TERM▾SCORE

% of 52-week high78%5

1-year return-13%3

3-year return-4%3

5-year return+0%4

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

It's down 13% over the past year, now 22% below its 52-week high. That is a touch behind the market.

Returns sit at the market level over the past month (-4%) and over three months (+0%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-3.6% over three years and +0.3% over five), behind 60% of the market.

The stock is underperforming so far this year (-17%).

BOTTOM LINE

Weak Tape

Returns across short and long horizons rank poorly versus the market. Momentum offers no support here; the case has to come from other factors. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on STERIS. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

STESTERIS

Revenue FY26$5.9B

GROWTH RATING↗

AVERAGE54 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+9%7

Revenue, next 1Y+7%5

Revenue, next 3Y, CAGR+7%5

Revenue, next 5Y, CAGR+6%6

EARNINGS FORECAST▾SCORE

EPS growth, FY27E+41%9

EPS growth, FY28E+9%6

EPS growth, FY29E+10%7

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 9%/yr over the last 3 years, ahead of 60% of companies worldwide.7/10

Earnings are set to grow in step with sales (EPS about 10%/yr vs revenue 7%/yr).

WATCH

A mid-pack grower, ahead of 54% of companies worldwide.

Revenue is set to grow 7%/yr over the next 3 years, in line with the market.5/10

Revenue grew 9%/yr over the last 3 years and is set to keep growing around 7%/yr.

Over five years revenue is set to grow 6%/yr, ahead of 50% of companies worldwide.6/10

WEAKNESSES

None flagged.

BOTTOM LINE

Margin Expander

A middle-of-the-pack grower. The one thing to watch: forward revenue growth is only about average.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

WEAK33 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-4%6

3-month return+0%6

YTD return-17%3

MID & LONG-TERM▾SCORE

% of 52-week high78%5

1-year return-13%3

3-year return-4%3

5-year return+0%4

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

It's down 13% over the past year, now 22% below its 52-week high. That is a touch behind the market.

Returns sit at the market level over the past month (-4%) and over three months (+0%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-3.6% over three years and +0.3% over five), behind 60% of the market.

The stock is underperforming so far this year (-17%).

BOTTOM LINE

Weak Tape

Returns across short and long horizons rank poorly versus the market. Momentum offers no support here; the case has to come from other factors. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on STERIS. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community